Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Rituximab Biosimilar (ODDIFACT) in Glioblastoma Multiforme: NCT06973096 Clinical Landscape Report 2026
28 September 2026
NCT06973096 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ERAS-801 in Glioblastoma Multiforme: NCT06934889 Clinical Landscape Report 2026
28 September 2026
NCT06934889 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sitagliptin Phosphate in Glioblastoma: NCT07003542 Clinical Landscape Report 2026
28 September 2026
NCT07003542 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Hormone receptor positive breast cancer: NCT07029399 Clinical Landscape Report 2026
28 September 2026
NCT07029399 clinical landscape for Hormone receptor positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06991101 Clinical Landscape Report 2026
28 September 2026
NCT06991101 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Ependymoma: NCT07031765 Clinical Landscape Report 2026
28 September 2026
NCT07031765 clinical landscape for Ependymoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Ovarian Cancer: NCT07038369 Clinical Landscape Report 2026
28 September 2026
NCT07038369 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07045311 Clinical Landscape Report 2026
28 September 2026
NCT07045311 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in PD-L1 positive Triple Negative Breast Cancer: NCT07040644 Clinical Landscape Report 2026
28 September 2026
NCT07040644 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Sacituzumab govitecan-hziy in Advanced Triple-Negative Breast Carcinoma: NCT07046455 Clinical Landscape Report 2026
28 September 2026
NCT07046455 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Sacituzumab tirumotecan in Triple Negative Breast Cancer: NCT07054242 Clinical Landscape Report 2026
28 September 2026
NCT07054242 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in Glioblastoma, IDH-Wildtype: NCT07047066 Clinical Landscape Report 2026
28 September 2026
NCT07047066 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.